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Objective. To evaluate the effect of nitric oxide (NO) on
acute pulmonary hypertension and right ventricular
function in patients with acute respiratory distress
syndrome.
Design. A prospective clinical study.
Patients. Ten patients in the respiratory and surgical
intensive care units were used. They met th~ criteria for
acute respiratory distress syndrome and were significantly
hypoxic. They were all ventilator-dependent at the time of
the study.
Intervention. NO was delivered to the patients in 5. 10,
20 and 30 ppm doses for 30 minutes at eac.h
concentration. The dosing was not randomised.
Measurements and results. The general and central
haemodynamics were measured. Right ventricular function
and interaction with the pulmonary artery impedance (Ea)
were quantified with the ratio of right ventricular stroke
work index/Ea.
NO did not decrease the raised pulmonary artery
pressure found in all of the patients. Right ventricular
coupling to the circulation did not improve during the
administration of NO.
Conclusion. NO did not relieve the acute pulmonary
artery hypertension associated with acute respiratory
distress syndrome. As a consequence of this, right
ventricular function failed to improve dUring the
administration of NO.
S At, Med J 1997; 87: 639-642.
In 1970 Clowes et al. documented right ventricular (RV)
dysfunction as the result of pulmonary hypertension
occurring in patients with peritonitis. 1 However, it was not
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until the report by zapol and Snider in 1977 that the
incidence and severity of pulmonary hypertension during
acute respiratory distress syndrome (ARD8) were finally
established.l
In a recent prospective study we documented severe
acute pulmonary hypertension (APHl) in 20 patients with
ARDS3 (patients with a Murray score in excess of 2.5
pointg4). In this study every patient had a significantly raised
mean pUlmonary artery pressure (PAP) at the time of
admission to the intensive care unit and thereafter the PAP
did not change much during the course of the illness. In
addition our data showed that RV failure occurred in each of
the patients. This published report supported a previous
retrospective analysis of 60 patients with ARDS who had
significant hypoxia (arterial haemoglobin saturation (Sa0J
< 90% while breathing an inspired oxygen fraction (FiOJ
> 0.8). In this analysis we found that 50% of patients had
significant RV failure in the presence of APHT (A Coetzee.
J Swanevelder - unpUblished data).
If APHT causes RV failure, the resultant mixed venous
blood haemoglobin desaturation will aggravate arterial
hypoxaemia associated with the pulmonary shunt of ARDS.
In addition, the raised PAP and pulmonary capillary pressure
will increase lung water and further increase the pulmonary
shunt.s-7 It is therefore clear that the reduction in PAP in the
presence of ARDS is of some importance in the
management of these critically ill patients.
The aim of this stUdy was to examine the effect of various
doses of nitric oxide (NO) on PAp, RV function and the
circulation in patients with ARDS.
Methods
Permission for this study was obtained from the Ethics
Committee of the University of Stellenbosch Medicai School.
Whenever possible, infonned consent was obtained from
patients or from close relatives.
Patients with ARDS admitted to the surgical and
respiratory intensive care units were selected according to
the criteria of Murray.· All the patients had arterial lines and
pulmonary artery catheters in situ as part of their clinical
management. They were ventilated with intermittent
mandatory ventilation (IMV) and pressure support (PS). The
FiO, and positive end-expired pressure (PEEP) were
adjusted in order to maintain an 8a02 > 90%. Pennissive
hypercapnia was used when necessary to limit the risk of
volume trauma to the lung and the pressure control mode
was usually used, allowing peak airway pressures up to
40 cm ~O. A capnograph monitored expired CO2 ,
For the study, NO (900 ppm NO in N, in a 1Q-litre
aluminium cylinder) was administered with the Pulmonox
system (Messer Griesheim, Austria). which was loaned to
the researchers by the Fedgas Co. ot South Africa. NO was
blended into the respiratory circuit of the ventilator while the
concentrations of NO in the endotracheal tube were
monitored. The generation of the toxic higher oxide of
nitrogen (NO,)' was constantly measured and remained
below 0.5 ppm during the study.
For the duration of the study, FiOl and ventilator settings
were left unaltered and 5, 10, 20 and 30 ppm of NO were
administered for'30 minutes each. Because of the very short
half-lije ot NO, it was not thought necessary to randomise
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Discussion
Fig 1. Mean PAP changes for each of the 10 patients exposed to
NO.
There is some scientific justification for the treatment of
APHT that occurs in association with ARDS. RV function
should improvelo-l~ and fluid transudation into the lungs







Table 11 summarises the systemic and central
haemodynamic data. The patients all had significant
pulmonary artery hypertension. The PAP did not decrease
significantly after the administration of NO although there
was a trend towards lower PAP values after the initial dose
of NO was administered (Fig. 1). In addition, no dose-related
change in the PAP could be demonstrated and little change
in the PAP was observed after the initial 5 ppm NO. The
CVP tended towards lower values after NO was initiated but
this failed to reach statistical significance. The Cl also
showed a tendency to increase after the administration of
NO but, as with the other variables, this numerical trend





In 2 patients there was no response in PAP and on
average the initial decrease therein was 2.9 ± 3.0 mmHg
(mean ± SD) at 5 ppm. At higher doses very little change,
over and above the initial reduction, could be demonstrated
(Taible 11).
Pulmonary gas exchange data are summarised in Table
Ill. The PEEP and FiO~ were kept constant for the duration of
the study. The pulmonary shunt did not improve and, as
expected, the Pa02 did not change. Any change occurred at
the 5 ppm step with little change thereafter.
In order to decide on the best index that could be used to
define RV function, correlations were attempted with SI as
the dependent variable. The following results were obtained:
SIIRVSWI - r = 0.37, SEE 8.67; SI/PVR - r = -0.62, SEE
7.39; SI/PAP - r =-0.70, SEE 6.67; SI/Ea - r =-0.82, SEE
5.43; SI/(RVSWI/Ea) - r = 0.95, SEE 3.11.
On the basis of these results it was decided to use the
ratio of RVSWllEa as the most suitable index to define the
RV-afterload interaction (ventricular-arterial coupling). This
ratio and the dose of NO demonstrated a poor correlation
(r = 0.09, (2 = 0.88%) and the ratio recorded during control
(zero NO) did not change with the administration of the
various doses of NO (Tabie Ill).
the doses. At the end of each test period, arterial and mixed
venous blood gases Oncluding the methaemoglobin
concentration) and ventilator settings were recorded.
Haemodynamic data recorded included: arterial pressure
and PAP, central venous pressure (CVP), pulmonary artery
wedge pressure (PAWP) and heart rate (HR). The cardiac
output (CO) was obtained wrth thermodilution performed in
triplicate with the injections performed throughout the
respiratory cycle. The CVP and PAWP were measured at the
end of expiration with the aid of an immobilised monitor
screen and cursor. For the pressure measurements, zero
was taken at the mid-axillary leveL
The FiO~, inspired and expired tidal volumes, PEEp, auto-
PEEP (dynamic hyperinflation), peak and plateau pressures
were recorded.
The following indices were calculated using standard
equations: mean arteriaVpulmonary artery pressure (MAP,
PAP); cardiac index (Cl); stroke index (SI); left and right
ventricular stroke work index (LVSWI and RVSWI); systemic
and pUlmonary artery vascular resistance; alveolar arterial
oxygen tension; arterial, mixed venous and capillary blood
oxygen content; pulmonary shunt; and pulmonary artery
elastance (Ea). The latter was calculated as the ratio of
systolic PAP/stroke volume and represents pulmonary artery
impedance, which is a measure of RV afterfoad.9 Oxygen
deliVery and oxygen consumption data from the various
patients were pooled, and the average and standard
deviation (SO) of the mean obtained. Data were analysed by
comparison of results obtained from the various
concentrations of NO Oncluding zero NO, Le. controO using
ANOVA and the multiple range test to define homogeneous
groups. For correlations the Pearson's (-method was used.
A probability of 0.05 was accepted as indicative of a
significant difference or association.
Data on 1 patient were incomplete and were not included in
the haemodynamic and gas exchange data. The
demographics ·of the patients and aetiology of the ARDS are
summarised in Table L The mean ARDS score (Murray) was
3.11 ± 0.67. Two of the patients survived their ARDS (20%).
Results
Table I. Demographic data, initial pathology and severity of the
patients included in the study
Oied (DV Murray
Gencer Age survived (5) Iniliai pathology score"
1 F 47 0 Mitral valve replacement 2.0
2 F 41 0 Diaphragm rupture 4.0
3 F 48 5 MuttitraumalMVA 3.5
4 F 26 0 Knife wound (abdomen); 3.25
massive blood transfusion
5 F 34 5 Multiple fractures; 3
pneumonia
6 F 26 0 Aspiration pneumonia 3.5
7 M 43 0 Perforated peptic ulcer 3.7
8 F 54 S Pneumonia 2.75
9 F 46 0 Diabetes, cardiac failure 2.25
10 M 53 0 Bilateral pneumonia! 3.0
tuberculosis
MVA '" motor vehicle acciderrt:.
Volume 87 No. 5 May 1997 SAMJ
CRITICAL CARE
Table 11. Systemic and central haemodynamics (mean ± SO) before and during the administration of NO (N = 9)
HR MAP PAP CVP PAWD Cl LVSWl RVSWI SVR PVR vc, DO, EA
(/Irin) ImmHg) ImmHg) 1n-mHg) ImmHg) (lIorWm') 19·mlm') 19·mlm') Id.sedan') (d.sedcm') I""rrin) IIrlImin) {mmHgI"'l RVSWIIEa
ConIroI 122.10 81.04 4124 15.00 14.60 4.61 35.54 12.81 701.32 297.90 236.69 1117.91 1.68 9.79
:t10.54 :10.18 :11.68 =4.12 :7.43 ±1.09 :i:12.31 ±J.01 ~143.68 ±133.17 ±41.59 :!::258.75 %1.12 :4.51
NO 122.40 81.71 38.28 14.70 14.20 4.70 36.64 11.75 684.6:3 258.78 253.75 1210.85 1.57 9.37
5_ :14.59 :11.72 :11.32 :4.00 :7.01 ±1.15 ±13.74 ..2n :123.92 ±105.11 ±48.23 ±202.73 %1.00 :14.31
NO 120.80 laS9 37.84 14.10 14.90 4.72 35.61 11.99 659.58 242.86 250.96 1223.50 1.51 9.76
10ppm :14.97 :2:11.62 :11.76 ±3.88 ±a.OB ±1.05 :13.42 ..290 :109.54 ~.45 ±SS.89 :203.62 .0.99 ±4.23
NO 121.90 79.86 37.76 13.40 14.90 4.85 36.89 12.57 664.42 235.29 250.05 1232.59 1.48 10.75
20ppm ±13.73 :13.50 :10.67 ±3.58 ±S.51 ±1.14 ±14.72 %2.84 ±115.94 :74.76 :56.76 ±240.69 .0.99 %525
NO 121.60 1lO.50 37.56 13.50 1S.eo 4.n 36.23 12.54 679.42 221.79 247.73 1235.05 1.41 10.6230_ :i:13.73 ±13.10 ±/l.82 ±J.B1 ±S.51 :1.07 ±14.OS ±3.33 ±128.09 ±SS.72 ±66.70 ±255.65 ±069 ±5.37
Signi1i- 0.999 0.993 0.948 0.87 0.995 0.993 0.994 0.937 0.957 0.512 0.970 0.978 0.982 0.966
cance IeYeI
Signiticance 1eYel: ANCNA between various NO concentralions.
HR '"' hean rate; MAP :: mean arterial pressure; PAP :: mean pulmonary artery pressure; cVP :: central venous pressure; PAWP :: pulmonary artery wedge ptessure; Cl : cardiac
index; lVSWVRVSWI :: left and right ventricular srroke work index; SVRlPVR '"' systerric and puImonaty vasaJlar resistance; VO. :: oxygen consumption; 00.:: oxygen delivery;
Ea :: pulmonary artery eIastance.
Table Ill. Pulmonary function (mean ± SO) during control and various concentrations of NO (N = 9)
Temp Pao, Sao, PaCo, Pv02 Sv02 OslO! PEEP
lOG) Fi<h (kPa) (%) IkPa) pH~ (kPa) 1%) (%) (cmH,Q)
Control 37.9 0.68 9.97 91.63 7.D5 7.37 5.43 12.61 39.1D 9.50
±1.21 :':0.21 ±.2.51 ±6.11 ±1.64 ±0.08 ±D.57 ±8.30 ±12.14 ±2.58
NO 37.92 D.68 11.15 93.56 7.25 7.35 5.75 73.83 35.00 9.50
5ppm ±126 ±D.21 ±3.09 ±4.10 ±1.41 ±D.07 ±D.54 ±5.88 ±13.15 ±2.58
NO 37.93 0.68 1D.78 93.77 7.06 7.36 5.76 74.22 36.00 9.50
10ppm ±1.27 ±D.21 ±.2.87 ±2.93 :±1.36 ±D.08 ±D.56 ±6.33 ±10.03 ±2.58
NO 37.99 0.68 10.67 92.85 7.21 7.36 5.63 73.54 38.10 9.70
20ppm ±123 ±D.21 =4.D4 =4.D5 ±1.35 ±D.08 ±D.56 ±5.36 ±15.15 ±3.03
NO 37.98 8.80 10.98 93.93 6.91 7.37 5.69 74.92 36.50 9.7D
30ppm ±124 ~4.42 ±3.55 ±3.12 .,.22 ±D.08 0.55 ±6.73 ±10.54 ±3.03
S;gn;ticance _ 0.992 D._ 0.951 D.771 D.!l86 0.!l86 0.714 0.962 0.957 D.999
~ 18Yel: ANOIA between various c:onc:entration 01 NO.
FIO,. :: inspted oxygen ffadion; PaO..~ '" arterial and rrDed venous ccygen partlaI prassure;~ = arterial arw::l' rnoced VM:IUS haernogIotwt saturatIOn. PaCO. =
parnaI presstft lor CO.; 0sI0t = putnonary stu1t: PEEP = po:5lti¥eend~ pntSSUl"&.
with direct vasodilators such as sodium nitroprusside,
nitroglycerine and prostaglandins are associated with
systemk: hypotension and the risk of ischaemk: RV failure. In
addition, because of interference with the pulmonary
vasoconstrictor response. they increase the pulmonary
shunt and this aggravates the existing difficulty in
oxygenating the patient.1:l-ltl
The phannacological profile of NO is theoretically ideally
suitable for the treatment of the problems of APHT.'
Because of its short half-life in vivo, its vasodilatory effect is
terminated by the time it reaches the systemic circulation. tt
therefore has little, if any, potential to cause systemic
hypotension if administered through the lung. Furthermore,
when NO is inhaled, it will only reach the alveoli with
effective ventilation and its effect will therefore be limited to
the capillaries of those alveoli. There is therefore little risk of
an increased pulmonary shunt.
The hypothesis for this study was that NO, because of its
known ability to dilate the pulmonary vascular bed,' will
reduce the PAP and thereby reduce the ejection pressure of
the RV. However, our data failed to show a significant
reduction in PAP when NO was administered. Neither the
change in absolute PAP, nor the difference in PAP
associated with the administration of NO, reached statistical
significance. We also failed to show a dose-related effect on
PAP and this suggests that increasing the number of
patients is unlikely to show a significant difference. As a
consequence of the failure to reduce PAP pressure and Ea
(the effective RV afterloadJ, RV coupling to the pulmonary
circulation did not benefit from the administration of NO.
The average (Insignificant) change we demonstrated in
PAP was of the order of 3 mmHg and 2 patients did not
respond when NO was administered. Previous reports have
also shown some patients to be non-responders to NO.'1.2D
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Our data are in contrast to those of Roissant et al., who
showed an improvement in RV ejection and RV end-diastolic
volume once the PAP was reduced by a mean of 5 mmHg.
This reduction in PAP was obtained with the administration
of 18 ppm NO to patients with ARDS.21 However, in their
study. despite the increase in RV ejection, the CO failed to
improve. In view of the fact that the CO was measured
directly as a function of RV function (thermodilution), the
constant CO in the face of an improved RV ejection fraction
cannot easily be explained. The authors speculate that the
absence of a reduction in SVR is responsible for the failure
of the CO to increase and refer to the increased CO that
occurred when, in their study, prostacycline was used.
Previous studies, conducted in animals with
thromboxane-induced pulmonary artery hypertensiona and
human volunteers with pulmonary hypertension induced with
alveolar hypoxia,22 demonstrated that NO reduces PAP.
Studies in human ARDS have also suggested a reduction in
PAP when patients were exposed to NO.17-'9 The study by
Roissant et aJ. evaluated the effect of NO on gas exchange
and PAP in 30 patients with ARDS.'9 They confirmed
improvement in gas exchange and in 63% of their patients
PAP was reduced by more than 3 mmHg (regarded as
responders). In absolute values, the mean decrease in PAP
they recorded was 4 mmHg but they failed to demonstrate
an improvement in cardiac output associated with this small
change in PAP. In another study by Roissant et aI.l1 the
authors showed a mean reduction in PAP of 7 mmHg while
Bigatello and colleagues demonstrated an average reduction
in PAP of only 4 mmHg.18 Gerlach et al. suggested that only
in ARDS patients with an initial mean PAP in excess of
45 mmHg was there a significant reduction in the PAP once
NO was given.2O
In our study we only used up to 30 ppm. This decision
was taken in light of the USA Occupation Safety and Health
Administration Standards which set the maximal working
exposure level for NO at 25 ppm (8 hours).22 In addition,
there is little data which supports the use of higher doses of
NO to improve outcome of these critically ill patients and it
was therefore decided not to use high concentrations of NO.
On re-evaJuation of the initial hypothesis it can justifiably
be asked whether there was sufficient reason to expect a
significant reduction in pulmonary artery pressure in patients
with ARDS. Although it is accepted that there is an eiement
of pulmonary vasospasm associated with the pulmonary
artery hypertension during ARDS, there is also evidence of
intravascular obstruction caused by clot fonnation in the
pulmonal)' arterial bed in patients with ARDS." NO will only
relieve arterial spasm and will not modify the intravascular
mechanical obstruction. How much of the raised PAP is due
to the clot fonnation and how much can be ascribed to
vasospasm has not been elucidated. Studies shOWing the
biggest reduction in PAP on the administration of NO were
obtained in experiments where the pUlmonary artery
hypertension was caused solely.by pulmonary arterial
vasospasm such as thromboxane- and aJveolar hypoxia-
induced pulmonary artery hypertension.'.2~There is probably
little reason to extrapolate these findings directfy to human
ARDS.
In conclusion, we failed to demonstrate a significant
reduction in PAP in patients suffering from AROS when
administering NO in concentrations of 5 - 30 ppm.
Because of this, there was also no improvement in RV
function or cardiac output. These results, seen against the
background of previous results which have shown
unpredictable and, at best, only small changes in PAPs
when NO was administered, make the rote of NO in the
treatment of APHT during ARDS doubtful. In addition,
studies to date have not demonstrated improved outcome in
patients with ARDS who received NO. There is therefore
currently little evidence to support the routine use of NO in
ARDS.
The study was supported by Fedgas SA
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